Addressing pain and the opioid crisis
Pain is a substantial public health issue, where it is estimated that about 100 million Americans need pain treatment. Opioids have been increasingly used to treat pain, with 50-90% of cancer patients needing such treatment. This has caused a concomitant rise in prescription opioid abuse and fatalities e.g. 42,249 drug fatalities in 2016 alone. Because of this, alternative treatment options are desperately needed, and more and more patients and doctors are looking to alternatives like cannabis for managing pain. Clinical translation of cannabinoids is severely limited by unwanted psychoactive side effects and lack of rigorous demonstration of therapeutic efficacy. The IPI is partnering with leading NFL players, athletes and affiliated industry partners to develop the highest quality evidence-based products to extend benefit to millions across the world in pain management, provide a viable alternative solution to the growing opioid crises in the USA, and help in alleviating the access abyss in palliative care and pain relief globally.
Reducing the side effects of Cancer treatment
Some studies have found that medical cannabis products can ease the side effects of chemotherapy and radiotherapy. The FDA has also approved dronabinol (Marinol, Syndros) and nabilone (Cesamet), man-made cannabinoids, to treat these symptoms when other nausea medications don’t work. We are investigating more effective products to minimize these effects for radiotherapy and chemotherapy treatment
Developing phytomedicines for Cancer, CTE, anemia leveraging nanodrones and collaborations across the world
We are accelerating research and development of evidence-based phytomedicines of the highest quality for different indications leveraging technology and unprecedented collaboration network across the world facilitated by the Global Health Catalyst summits